Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2025-524723-52-00
Authorised, not yet recruiting Phase III

LIBRETTO: Stimulan™ Local Antibiotic Delivery System Versus 4-Week Systemic Antibiotic Therapy for Diabetic Foot Osteomyelitis – A Prospective, Randomized, Controlled Trial

2025-524723-52-00 · tracked via the Priya Life Science EU tracker
Sponsor
Pirkanmaan hyvinvointialue
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Bacterial Infections and Mycoses
Decision date
10/04/2026
Enrollment target
84
Sites
Finland

Condition studied

Diabetic Foot Osteomyelitis

Investigational medicinal product(s)

Gensumycin 40 mg/ml injektionesteliuosCotrim forte tabletitMeropenem AptaPharma 1 g injektio-/infuusiokuiva-aineliuosta vartenAmoxin comp 500 mg / 125 mg tablettikalvopäällysteinenMetronidazole Braun 5 mg/ml infuusionesteVancomycin MIP Pharma 1000 mgInfuusiokuiva-aineCefuroxim MIP Pharma 1500 mg injektio/infuusiokuiva-aineKefexin 750 mg tablettiPiperacillin/Tazobactam Fresenius Kabi 4 g/0,5 g infuusiokuiva-aineCiprofloxacin Orion 500 mg kalvopäällysteiset tabletitClindamycin Orion 300 mg kapselikovaVancomycin MIP Pharma 500 mgDoximed 100 mg tablettiTrikozol 400 mg tabletitFlucloxacillin Orion 1 g kalvopäällysteiset tabletitLevofloxacin Orion 500 mg kalvopäällysteiset tabletitCeftriaxon Fresenius Kabi 2 g infuusiokuiva-aineAmoxicillin MIP Pharma 1000 mg tabletit

Every trial of Clindamycin, Ciprofloxacin, Levofloxacin and Metronidazole across our registers →

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

• Healed ulcer/osteomyelitis resolution at 12 and 24 weeks (no further antimicrobial treatment, stable wound closure)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524723-52-00 on CTIS ↗ ← All trials in the EU